Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation is a clinical trial[1].
Key Facts
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation is in the country of Germany[2].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation is in the country of Italy[3].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation is in the country of Spain[4].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation is in the country of Sweden[5].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's instance of is recorded as clinical trial[6].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's start time is recorded as +2011-11-30T00:00:00Z[7].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's end time is recorded as +2017-06-30T00:00:00Z[8].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's sponsor is recorded as An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when[9].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's main subject is recorded as multiple myeloma[10].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's number of participants is recorded as {'unit': '1', 'amount': '+49'}[11].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's title is recorded as European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients[12].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's short name is recorded as EMN-alloRIC[13].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[14].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's ClinicalTrials.gov ID is recorded as NCT01460420[15].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+70'}[16].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's research intervention is recorded as (RS)-lenalidomide[17].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's research intervention is recorded as bortezomib[18].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's clinical trial phase is recorded as phase I clinical trial[19].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's clinical trial phase is recorded as phase II clinical trial[20].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's research subject recruitment status is recorded as completed[21].
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation's study type is recorded as interventional study[22].